Stratification of T2DM and CAD + T2DM patients in the primary cohort by short-term SGLT2 inhibitor administration status revealed that SGLT2 inhibitor users had 0.917-fold lower MRV(Venular)C vs. non-users (P = 0.002, 95% CI: 0.867–0.969), exhibiting reduced MRV(Venular)C0.5–1.0PD (OR = 0.917, P < 0.001, 95% CI: 0.874–0.962) and MRV(Venular)C1.0–1.5PD (OR = 0.948, P = 0.034, 95% CI: 0.902–0.996) (Supplementary Table S17), signifying SGLT2 inhibitors' retinal lesion improvement effect. The gene discussed is SLC5A2; the disease is coronary artery disorder.